Asensus Surgical (Asensus Surgical) Risk Assessment

View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Asensus Surgical is: High Risk: High uncertainty.

Competitive Comparison of Asensus Surgical's Risk Assessment

For the Medical Devices subindustry, Asensus Surgical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asensus Surgical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's Risk Assessment falls into.

Asensus Surgical (AMEX:ASXC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Asensus Surgical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (Asensus Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

2TX:Germany

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Executives

Starling William N Jr	director	2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi	director	C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert	director	343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J.	officer: Chief Technology Officer	635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze	officer: EVP, Chief Financial Officer	C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh	officer: Interim CFO	108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery	officer: EVP and CFO	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith	officer: Chief Commercial Officer	7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope	director, officer: President and CEO	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a	10 percent owner	VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022